Beginning Monday, April 17th

The Iowa Cancer Mutation Profile assay from the Molecular Pathology laboratory will be updated to include targets for the identification of substitutions and small insertion/deletions in the VHL gene. CHEK2 coverage will be expanded to cover all exons.

Key features:

• Substitutions and small insertion/deletions are detected in these genes:
  
  ABL1, ACVR1, AKT1, AKT2, AKT3, ALK, ANKRD26, APC, AR, ARAF, ARID1A, ATM, ATR, ATRX, AURKA, AXL, BAP1, BARD1, BIRC3, BLM, BRAF, BRCA1, BRCA2, BRIP1, BTK, CBL, CCND1, CCND2, CCND3, CCNE1, CD28, CDH1, CDK12, CDK2, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CHEK1, CHEK2, CIC, CREBBP, CRKL, CSF1R, CSF3R, CTNNB1, DAXX, DDR2, DDX3X, DHX15, DICER, DNMT3A, DOT1L, EED, EGFR, EPHA3, ERBB2, ERBB3, ERBB4, ERCC2, ERRFI1, ESR1, ETNK1, ETV6, EZH2, FAM175A, FANCA, FANCC, FANCD2, FANCI, FANCL, FBXW7, FGF19, FGF3, FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT3, FOXL2, FUBP1, GATA1, GATA2, GATA3, GNA11, GNAQ, GNAS, H3F3A, HIST1H3B, HIST1H3C, HNF1A, HRAS, IDH1, IDH2, IGF1R, IGF2, JAK1, JAK2, JAK3, KDR, KEAP1, KIT, KLR4, KMT2D, KNSTRN, KRAS, MAGOH, MAP2K1, MAP2K2, MAP2K4, MAPK1, MAPK3, MAX, MCL1, MDM2, MDM4, MED12, MET, MLH1, MPL, MRE11A, MSH2, MSH6, MTOR, MYC, MYCL, MYCN, MYD88, NBN, NF1, NF2, NFE2L2, NFKBIA, NOTCH1, NOTCH2, NOTCH3, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PDGFRA, PDGFRB, PHF6, PIK3CA, PIK3CB, PIK3R1, PIK3R2, PLCG2, PMS2, POLD1, POLE, PPARG, PPP2R1A, PTCH1, PTEN, PTPN11, RAC1, RAD21, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAF1, RB1, RET, RHEB, RHOA, RICTOR, RNF43, ROS1, SDHA, SDHB, SDHC, SDHD, SETBP1, SETD2, SF3B1, SF3B1, SIRT2, SLIT2, SLX4, SMAD4, SMARCA4, SMARCB1, SMC1A, SMC3, SMO, SOX2, SPOP, SRC, SRSF2, STAT3, STAT5B, STK11, SUFU, TERT, TET2, TOP1, TP53, TRAF7, TSC1, TSC2, TYK2, U2AF1, U2AF2, VHL, WT1, XPO1, and ZBTB7A
  
  
• Copy number alterations (gains or losses) are detected in these genes: AKT1, AKT2, AKT3, ALK, AR, AXL, BRAF, CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN2A, CDKN2B, EGFR, ERBB2, ESR1, FGF19, FGF3, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, IGF1R, KIT, KRAS, MDM2, MDM4, MET, MYC, MYCL, MYCN, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PPARG, PTEN, RICTOR, SOX2, TERT, TSC1, and TSC2
  
  
• FDA approved drugs may be available in association with particular mutation profiles for many of the gene targets included in this testing, dependent on tumor type and treatment strategy.

Questions can be directed to Deqin Ma, MD, Molecular Laboratory Director (384-5700, deqin-ma@uiowa.edu) or Sarah Hornberg, Molecular Laboratory Supervisor (384-9870, sarah-hornberg@uiowa.edu).